Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer.

Cell penetrating peptides (CPPs) are short amphipathic and cationic peptides that are rapidly internalized across cell membranes. They can be used to deliver molecular cargo, such as imaging agents (fluorescent dyes and quantum dots), drugs, liposomes, peptide/protein, oligonucleotide/DNA/RNA, nanoparticles and bacteriophage into cells. The utilized CPP, attached cargo, concentration and cell type, all significantly affect the mechanism of internalization. The mechanism of cellular uptake and subsequent processing still remains controversial. It is now clear that CPP can mediate intracellular delivery via both endocytic and non-endocytic pathways. In addition, the orientation of the peptide and cargo and the type of linkage are likely important. In gene therapy, the designed cationic peptides must be able to 1) tightly condense DNA into small, compact particles; 2) target the condensate to specific cell surface receptors; 3) induce endosomal escape; and 4) target the DNA cargo to the nucleus for gene expression. The other studies have demonstrated that these small peptides can be conjugated to tumor homing peptides in order to achieve tumor-targeted delivery in vivo. On the other hand, one of the major aims in molecular cancer research is the development of new therapeutic strategies and compounds that target directly the genetic and biochemical agents of malignant transformation. For example, cell penetrating peptide aptamers might disrupt protein-protein interactions crucial for cancer cell growth or survival. In this review, we discuss potential functions of CPPs especially for drug and gene delivery in cancer and indicate their powerful promise for clinical efficacy.

[1]  L. Worley,et al.  Transducible peptide therapy for uveal melanoma and retinoblastoma. , 2002, Archives of ophthalmology.

[2]  D. Sheppard,et al.  A novel peptide, PLAEIDGIELTY, for the targeting of α9β1‐integrins , 1998, FEBS Letters.

[3]  Ű. Langel,et al.  The use of cell-penetrating peptides as a tool for gene regulation. , 2004, Drug discovery today.

[4]  Vladimir P Torchilin,et al.  Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. , 2008, Biopolymers.

[5]  T. Sawamura,et al.  Identification of Peptides That Target the Endothelial Cell–Specific LOX-1 Receptor , 2001, Hypertension.

[6]  R. Lukaszewski,et al.  VP22 enhances antibody responses from DNA vaccines but not by intercellular spread. , 2005, Vaccine.

[7]  Gong Yang,et al.  The inflammatory network: bridging senescent stroma and epithelial tumorigenesis. , 2009, Frontiers in bioscience.

[8]  J. Reimann,et al.  Peptides containing antigenic and cationic domains have enhanced, multivalent immunogenicity when bound to DNA vaccines , 2004, Journal of Molecular Medicine.

[9]  S Uebel,et al.  Recognition principle of the TAP transporter disclosed by combinatorial peptide libraries. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[10]  M. Morris,et al.  A non-covalent peptide-based strategy for ex vivo and in vivo oligonucleotide delivery. , 2011, Methods in molecular biology.

[11]  E. Vivés,et al.  Tat peptide-mediated cellular delivery: back to basics. , 2005, Advanced drug delivery reviews.

[12]  Roger Y Tsien,et al.  Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. , 2009, Integrative biology : quantitative biosciences from nano to macro.

[13]  R. Reilly,et al.  HIV-1 Tat peptide immunoconjugates differentially sensitize breast cancer cells to selected antiproliferative agents that induce the cyclin-dependent kinase inhibitor p21WAF-1/CIP-1. , 2006, Bioconjugate chemistry.

[14]  Marie Carrière,et al.  NLS bioconjugates for targeting therapeutic genes to the nucleus. , 2003, Advanced drug delivery reviews.

[15]  M. Morris,et al.  Cell-penetrating peptides: tools for intracellular delivery of therapeutics , 2005, Cellular and Molecular Life Sciences CMLS.

[16]  M. Imamura,et al.  Trojan p16 peptide suppresses pancreatic cancer growth and prolongs survival in mice. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  Ülo Langel,et al.  Design of a Tumor Homing Cell-Penetrating Peptide for Drug Delivery , 2009, International Journal of Peptide Research and Therapeutics.

[18]  M. Morris,et al.  Cell‐penetrating peptides: from molecular mechanisms to therapeutics , 2008, Biology of the cell.

[19]  Xuetao Cao,et al.  Systemic genetic transfer of p21WAF−1 and GM-CSF utilizing of a novel oligopeptide-based EGF receptor targeting polyplex , 2003, Cancer Gene Therapy.

[20]  W. Seeger,et al.  Nano-carriers for DNA delivery to the lung based upon a TAT-derived peptide covalently coupled to PEG-PEI. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[21]  Z. Shang,et al.  In vitro effects of nitric oxide synthase inhibitor L-NAME on oral squamous cell carcinoma: a preliminary study. , 2006, International journal of oral and maxillofacial surgery.

[22]  Steven F. Dowdy,et al.  Cell Penetrating Peptides in Drug Delivery , 2004, Pharmaceutical Research.

[23]  B. Lebleu,et al.  Cell penetrating peptides: overview and applications to the delivery of oligonucleotides , 2010, Cellular and Molecular Life Sciences.

[24]  C. Gelfand,et al.  Intrinsic peptidase activity causes a sequential multi-step reaction (SMSR) in digestion of human plasma peptides. , 2008, Journal of proteome research.

[25]  A. Bolhassani,et al.  Leishmania major: Protective capacity of DNA vaccine using amastin fused to HSV-1 VP22 and EGFP in BALB/c mice model. , 2011, Experimental parasitology.

[26]  Erich A. Nigg,et al.  Nucleocytoplasmic transport: signals, mechanisms and regulation , 1997, Nature.

[27]  J. Temsamani,et al.  The use of cell-penetrating peptides for drug delivery. , 2004, Drug discovery today.

[28]  S. Akira,et al.  Antigenic Epitopes Fused to Cationic Peptide Bound to Oligonucleotides Facilitate Toll-Like Receptor 9-Dependent, but CD4+ T Cell Help-Independent, Priming of CD8+ T Cells1 , 2003, The Journal of Immunology.

[29]  G. Colombo,et al.  Rational design of shepherdin, a novel anticancer agent. , 2005, Cancer cell.

[30]  Kairong Wang,et al.  Design of acid-activated cell penetrating peptide for delivery of active molecules into cancer cells. , 2011, Bioconjugate chemistry.

[31]  B. Groner,et al.  Bifunctional recombinant proteins in cancer therapy: cell penetrating peptide aptamers as inhibitors of growth factor signaling , 2003, Journal of Cancer Research and Clinical Oncology.

[32]  L. Seymour,et al.  Harnessing nuclear localization pathways for transgene delivery. , 2001, Current opinion in molecular therapeutics.

[33]  Y. Tseng,et al.  Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study. , 2002, Molecular pharmacology.

[34]  K. Rice,et al.  Peptide-mediated gene delivery: influence of peptide structure on gene expression. , 1997, Bioconjugate chemistry.

[35]  L. Neckers,et al.  Heat shock protein 90 as a molecular target for cancer therapeutics. , 2003, Cancer cell.

[36]  Y. Soini,et al.  eNOS expression is associated with the estrogen and progesterone receptor status in invasive breast carcinoma. , 2000, International journal of oncology.

[37]  R. Juliano,et al.  Cell-targeting and cell-penetrating peptides for delivery of therapeutic and imaging agents. , 2009, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[38]  R. Kennedy,et al.  Induction of nuclear transport with a synthetic peptide homologous to the SV40 T antigen transport signal , 1986, Cell.

[39]  M. De Waard,et al.  Efficient induction of apoptosis by doxorubicin coupled to cell-penetrating peptides compared to unconjugated doxorubicin in the human breast cancer cell line MDA-MB 231. , 2009, Cancer letters.

[40]  A. Bolhassani,et al.  The efficiency of a novel delivery system (PEI600-Tat) in development of potent DNA vaccine using HPV16 E7 as a model antigen , 2009, Drug delivery.

[41]  V. Apostolopoulos,et al.  Cell-penetrating peptides: application in vaccine delivery. , 2010, Biochimica et biophysica acta.

[42]  R. Juliano Challenges to macromolecular drug delivery. , 2007, Biochemical Society transactions.

[43]  C. Beattie,et al.  Noncationic peptides obtained from azurin preferentially enter cancer cells. , 2009, Cancer research.

[44]  Azam Bolhassani,et al.  Improvement of different vaccine delivery systems for cancer therapy , 2011, Molecular Cancer.

[45]  千葉 之宣 The novel peptide , 1990 .

[46]  M. Manns,et al.  VP22-mediated intercellular transport of p53 in hepatoma cells in vitro and in vivo , 2002, Cancer Gene Therapy.

[47]  A. Gartel,et al.  The Role of the Cyclin-dependent Kinase Inhibitor p 21 in Apoptosis 1 , 2002 .

[48]  Shu Wang,et al.  Enhanced gene delivery to PC12 cells by a cationic polypeptide. , 2005, Biomaterials.

[49]  Roger Y Tsien,et al.  In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. , 2009, Integrative biology : quantitative biosciences from nano to macro.

[50]  D. Mukhopadhyay,et al.  The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion. , 2001, Cancer research.

[51]  P. Collas,et al.  Nuclear localization signal of SV40 T antigen directs import of plasmid DNA into sea urchin male pronuclei in vitro , 1996, Molecular reproduction and development.

[52]  H. Moroson Polycation- treated tumor cells in vivo and in vitro. , 1971, Cancer research.

[53]  H. Zentgraf,et al.  Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. , 2002, Virology.

[54]  L. Smith,et al.  Peptide-based gene delivery. , 1999, Current opinion in molecular therapeutics.

[55]  A. Prochiantz,et al.  Introduction of exogenous antigens into the MHC class I processing and presentation pathway by Drosophila antennapedia homeodomain primes cytotoxic T cells in vivo. , 1996, Journal of immunology.

[56]  E. Kokkoli,et al.  Peptide- and aptamer-functionalized nanovectors for targeted delivery of therapeutics. , 2009, Journal of biomechanical engineering.

[57]  E. Snyder,et al.  Enhanced targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by transducible anticancer peptides. , 2005, Cancer research.

[58]  Yue-Wern Huang,et al.  A gene delivery system for human cells mediated by both a cell-penetrating peptide and a piggyBac transposase. , 2011, Biomaterials.

[59]  Nucleocytoplasmic Transport , 1996, Science.

[60]  F. Alexis,et al.  Covalent Attachment of Low Molecular Weight Poly(ethylene imine) Improves Tat Peptide Mediated Gene Delivery , 2006 .

[61]  V. Bloomfield,et al.  DNA condensation. , 1996, Current opinion in structural biology.

[62]  K. Rice,et al.  A Potent New Class of Reductively Activated Peptide Gene Delivery Agents* , 2000, The Journal of Biological Chemistry.

[63]  R. Werner,et al.  Potent enhancement of GFP uptake into HT-29 cells and rat skin permeation by coincubation with tat peptide. , 2011, Journal of pharmaceutical sciences.

[64]  Roger D. Kornberg,et al.  Synthetic peptides as nuclear localization signals , 1986, Nature.

[65]  K. Cahill,et al.  Cell-penetrating peptides, electroporation and drug delivery. , 2010, IET systems biology.

[66]  Vladimir P Torchilin,et al.  Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. , 2005, Advanced drug delivery reviews.

[67]  Michael I. Wilson,et al.  Peptide blockade of HIFα degradation modulates cellular metabolism and angiogenesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[68]  Yong Wang,et al.  Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor–coactivator interactions , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[69]  E. Wagner,et al.  Specific systemic nonviral gene delivery to human hepatocellular carcinoma xenografts in SCID mice , 2002, Hepatology.

[70]  Kevin G. Rice,et al.  Peptide-guided gene delivery , 2007, The AAPS Journal.

[71]  Benjamin G. Bitler,et al.  Anti-cancer therapies that utilize cell penetrating peptides. , 2010, Recent patents on anti-cancer drug discovery.

[72]  Ü. Langel,et al.  Cell-Penetrating Peptides , 2000, Methods in Molecular Biology.

[73]  J. Ajani,et al.  Expression of endothelial nitric oxide synthase correlates with the angiogenic phenotype of and predicts poor prognosis in human gastric cancer , 2005, Gastric Cancer.

[74]  Sanjeev Banerjee,et al.  Ursolic acid inhibits nuclear factor-kappaB activation induced by carcinogenic agents through suppression of IkappaBalpha kinase and p65 phosphorylation: correlation with down-regulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1. , 2003, Cancer research.

[75]  R. Mahato Non-viral peptide-based approaches to gene delivery. , 1999, Journal of drug targeting.

[76]  Joseph Rosenecker,et al.  Application of Novel Solid Lipid Nanoparticle (SLN)-Gene Vector Formulations Based on a Dimeric HIV-1 TAT-Peptide in Vitro and in Vivo , 2004, Pharmaceutical Research.

[77]  C. Berkland,et al.  Calcium condensation of DNA complexed with cell-penetrating peptides offers efficient, noncytotoxic gene delivery. , 2011, Journal of pharmaceutical sciences.

[78]  M. Buschle,et al.  Binding immune‐stimulating oligonucleotides to cationic peptides from viral core antigen enhances their potency as adjuvants , 2002, European journal of immunology.

[79]  J. Seelig,et al.  The cationic cell-penetrating peptide CPP(TAT) derived from the HIV-1 protein TAT is rapidly transported into living fibroblasts: optical, biophysical, and metabolic evidence. , 2005, Biochemistry.

[80]  K. Ingvarsdóttir,et al.  Association of the herpes simplex virus major tegument structural protein VP22 with chromatin. , 2010, Biochimica et biophysica acta.

[81]  Ernst Wagner,et al.  Targeting tumors with non-viral gene delivery systems. , 2002, Drug discovery today.

[82]  M. Flessner,et al.  Inhibition of ovarian cancer cell metastasis by a fusion polypeptide Tat-ELP , 2009, Clinical & Experimental Metastasis.

[83]  J Barsoum,et al.  Tat-mediated delivery of heterologous proteins into cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[84]  G. Shipulin,et al.  [Progress in gene therapy]. , 2011, Terapevticheskii arkhiv.

[85]  J. Butel,et al.  Construction and characterization of an SV40 mutant defective in nuclear transport of T antigen , 1984, Cell.

[86]  K. Rice,et al.  Metabolic stability of glutaraldehyde cross-linked peptide DNA condensates. , 1999, Journal of pharmaceutical sciences.

[87]  J. Huo,et al.  p53-independent induction of p21waf1/cip1 contributes to the activation of caspases in GTP-depletion-induced apoptosis of insulin-secreting cells , 2004, Cell Death and Differentiation.

[88]  G. Tang,et al.  Gene delivery to tumor cells by cationic polymeric nanovectors coupled to folic acid and the cell-penetrating peptide octaarginine. , 2011, Biomaterials.

[89]  Li Jiang,et al.  MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation , 2011, Molecular Cancer.

[90]  S. Futaki Membrane-permeable arginine-rich peptides and the translocation mechanisms. , 2005, Advanced drug delivery reviews.

[91]  Zhang Ji,et al.  C57BL/6および129SvEvマウス間の大動脈弓形状,血行動態,プラークパッターンの相異 | 文献情報 | J-GLOBAL 科学技術総合リンクセンター , 2009 .

[92]  Astrid Gräslund,et al.  Mechanisms of Cellular Uptake of Cell-Penetrating Peptides , 2011, Journal of biophysics.

[93]  Sanjeev Banerjee,et al.  Ursolic Acid Inhibits Nuclear Factor-κB Activation Induced by Carcinogenic Agents through Suppression of IκBα Kinase and p65 Phosphorylation: Correlation with Down-Regulation of Cyclooxygenase 2, Matrix Metalloproteinase 9, and Cyclin D1 , 2003 .